The drug for amyotrophic lateral sclerosis has impressed neurologists

In a small study, a biotech company has tested its own amyotrophic lateral sclerosis drug.

Today, there are several treatment methods available for patients with amyotrophic lateral sclerosis (ALS), but all of them are far from positive standards. Therefore, experimental drug AMX0035 has attracted close attention of experts, because it has shown signs of improved survival in early-stage studies. The company Amylyx Pharmaceuticals from Cambridge has conducted a study. This study has shown that AMX0035 slows functional decline in patients with rapidly progressive ALS. In the analysis of this trial, it was noted that from the start of the study, patients who initially received AMX0035 lived generally 6.5 months longer than patients in the control group.

Although the drug has generated noise among neurologists, scientists admit that it is not a panacea. Patients who received this drug still showed functional decline.

SOURCE: BIOPHARMA DIVE